US › Healthcare

Pacira BioSciences, Inc. (PCRX)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$27.62+2.60%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$177.4M
Revenue YoY
+5.0%
Net profit
$2.9M
Profit YoY
-39.4%
EPS
$0.60
EPS estimate
$0.56
Net margin
1.6%

EPS came in at 0.60 against a street estimate of 0.56 — a beat of 7.1%.

Key statistics

Market cap
$1.04B
P/E
203.2
Forward P/E
9.0
P/B
1.59
Book value
$16.63
EPS (TTM)
$0.13
52-week high
$27.64
52-week low
$18.80
50-day MA
$24.43
200-day MA
$23.48
Beta
0.27

Analyst view

Analysts rate Pacira BioSciences, Inc. a buy (4 buy, 2 hold, 1 sell out of 7) with an average price target of $29.67.

Shareholding

Insiders
1.77%
Institutions
115.28%

Largest institutional holders

FundStake
BlackRock Inc17.12%
Vanguard Group Inc12.24%
Doma Perpetual Capital Management LLC7.06%
Vanguard Portfolio Management, LLC6.36%
Dimensional Fund Advisors, Inc.5.24%
D. E. Shaw & Co LP5.04%
State Street Corp4.88%
Renaissance Technologies Corp4.64%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pacira BioSciences, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.